Aclarion Inc, a healthcare technology company at the forefront of leveraging biomarkers and proprietary augmented intelligence algorithms, announced a significant development today. Aclarion has executed a strategic partnership agreement with Alphatec Spine, Inc., the wholly owned operating subsidiary of Alphatec Holdings Inc., solidifying a previously signed non-binding Letter of Intent (LOI). This partnership aims to revolutionize the identification and treatment of chronic low back pain (cLBP) by combining Aclarion’s innovative Nociscan solution with ATEC’s AlphaInformatiX platform.
The announcement triggered a remarkable surge in Aclarion’s stock during pre-market trading, with shares opening at $6.57 on Monday morning after closing at $3.06 on the preceding Friday.
At the time of this publication, Aclarion Inc stock (ACON) has witnessed a surge.
Aclarion Inc
Current Price: $4.17
Change : +1.11
Change (%): (36.40%)
Volume: 20.7M
Source: Tomorrow Events Market Data
The collaboration will integrate ATEC’s unique structural information from its AlphaInformatiX platform with Aclarion’s biomarker data, enabling surgeons to access unprecedented data on a single platform. This platform is designed to enhance clinical outcomes and reduce procedural costs for patients suffering from chronic low back pain.
The strategic partnership outlines a multi-step plan where Aclarion and Alphatec commit to working together to identify key opinion leader (KOL) surgeons to evaluate the Nociscan technology. Surgeon feedback will inform clinical evaluations, assessing the utility of Nociscan alongside EOS imaging, the foundation of ATEC’s AlphaInformatiX platform. As positive synergies emerge, the companies plan to co-market Nociscan in targeted markets. Aclarion has agreed to provide ATEC with exclusive distribution rights in exchange for select access to ATEC’s surgeon network.
ATEC’s Chairman and CEO, Pat Miles, expressed enthusiasm about the shared vision between the two companies, emphasizing the efficient progression from the LOI to the agreement. Miles highlighted the mutual goal of integrating and advancing technologies to improve spine patient care predictability and reproducibility.
Aclarion’s proprietary decision-support tool, Nociscan, is a groundbreaking evidence-supported SaaS platform that noninvasively helps physicians differentiate between painful and nonpainful discs in the lumbar spine. The platform objectively quantifies chemical biomarkers associated with disc pain, aiding physicians in optimizing treatment strategies by identifying the source of a patient’s low back pain.
Published trials confirm Nociscan’s comparative advantage in achieving differentiated surgical outcomes. A peer-reviewed publication in April 2023 demonstrated an 85% success rate at two years for discogenic low back pain surgeries consistent with Nociscan-identified discs, a significant improvement over inconsistent strategies (85% vs. 63%; p=0.07).
Brent Ness, CEO of Aclarion, emphasized the acceleration of progress through the partnership with ATEC, citing KOL advocacy, evidence accumulation, and increasing scan volume as crucial elements. Ness expressed confidence that bundling Nociscan with ATEC’s AlphaInformatiX platform would lead to better outcomes, a thesis they aim to prove in the coming months.
Chronic low back pain affects approximately 266 million people worldwide, and conventional imaging and diagnostics have limitations in identifying the source of pathogenic pain. The Aclarion and ATEC partnership seeks to address this global healthcare problem with innovative solutions, combining cutting-edge technology and medical expertise to provide better outcomes for patients suffering from chronic low back pain.
